ArticleThe oncologist2025
Prognosis in stage II colorectal cancer: the effect of the primary tumor location and biomarkers-a retrospective cohort study.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe prognostic impact of primary tumor location (right- vs left-sided) is well-established in stage III/IV colorectal cancer (CRC), with right-sided tumors associated with poorer outcomes. However, its prognostic role in stage II CRC remains unclear. This study investigates whether the worse outcomes observed in advanced right-sided cancers also apply to early-stage CRC, or if they may be influenced by other factors such as patient demographics and molecular biomarkers. Clarifying this could help improve risk stratification in clinical practice. METHODOLOGY: For this study, we analyzed data of all Belgian patients diagnosed with stage II CRC in 2015-2016 (n = 3.278, data obtained from the Belgian Cancer Registry). Information on primary tumor location, demographics, pathologic T-category, molecular biomarkers (including microsatellite instability [MSI], BRAF, and KRAS status), and overall survival (OS) was collected.
resultsIn the univariable analysis, patients with stage II right-sided colon cancer had a significantly worse OS than left-sided colon cancer. Furthermore, advanced age and pT4 were also associated with worse OS. However, in the multivariable analysis, only gender, age, and pathologic T-category significantly affected OS. Primary tumor location was not significantly associated with OS in the multivariable analysis. Furthermore, the molecular biomarkers did not show a significant effect in either analysis. However, due to the limited size of the multivariable cohort, these results should be interpreted with caution.
conclusionThe primary tumor location is not an independent prognostic factor in stage II CRC with a confounding effect of age. Notably, -molecular biomarkers did not affect the prognosis in either uni- or multivariable analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.